BridgeBio Pharma (BBIO) Gross Margin (2020 - 2026)

BridgeBio Pharma has disclosed Gross Margin across 7 years of filings, most recently posting 94.89% for Q1 2026.

• Gross Margin for Q1 2026 came in at 94.89%, down 285.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 95.13% (down 23.0% YoY), and the FY2025 annual result was 95.82%, down 243.0% from the prior year.
• Gross Margin came in at 94.89% for Q1 2026 at BridgeBio Pharma, roughly flat from 94.74% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 99.72% in Q1 2024 to a low of 118.64% in Q3 2022.
• The 5-year median for Gross Margin is 81.75% (2023), against an average of 69.89%.
• Across the five-year window, Gross Margin plunged 15661 bps in 2022 and soared 20402 bps in 2023, its largest moves.
• BridgeBio Pharma's Gross Margin stood at 65.4% in 2022, then advanced by 1 bps to 65.73% in 2023, then retreated by 2 bps to 64.57% in 2024, then jumped by 47 bps to 94.74% in 2025, then increased by 0 bps to 94.89% in 2026.
• The last three Gross Margin figures came in at 94.89% (Q1 2026), 94.74% (Q4 2025), and 94.56% (Q3 2025), per Business Quant data.